-
March 08, 2013
GlaxoSmithKline has announced the submission of a marketing authorisation application for albiglutide, which will have the brand name Eperzan, to the European Medicines Agency
Full story
-
January 15, 2013
GlaxoSmithKline has submitted an application US regulators seeking approval to market its investigational GLP-1 receptor agonist albiglutide for the treatment of adults with type II diabetes.
Full story
-
July 16, 2012
The rumours were right and GlaxoSmithKline has won the day to acquire Human Genome Sciences, raising its original offer by $1.25 to $14.25 per share.
Full story
-
July 12, 2012
UK drug giant GlaxoSmithKline is planning to file for approval of albiglutide as a diabetes treatment early next year, after the drug turned in a solid performance in its Phase III clinical trial programme.
Full story
-
May 18, 2012
Human Genome Sciences has adopted a shareholder rights plan in the face of GlaxoSmithKline's hostile offer and has again dismissed the latter's $2.60 billion bid as inadequate
Full story
-
April 20, 2012
In confirming its unsolicited $2.60 billion bid for Human Genome Sciences, which has been rejected, GlaxoSmithKline says it still hopes to push through the deal "on a friendly basis"
Full story
-
April 03, 2012
GlaxoSmithKline says it intends to file its investigational diabetes drug albiglutide on the back of data from seven of eight Phase III studies
Full story
-
November 17, 2011
GlaxoSmithKline has posted data from a late-stage study which shows that its investigational glucagon-like peptide-1 agonist albiglutide failed to show non-inferiority to Novo Nordisk's Victoza in patients with type 2 diabetes
Full story